利用中美冠科數據庫,快速查找所需模型
OncoExpress|HuBase|XenoBase|MuBase

白皮書

中美冠科生物通過協助生物制藥公司解決當今腫瘤學和心血管與代謝疾病中最緊迫的問題為世界藥物研發帶來曙光。

With the continued rise of immunotherapeutics, more preclinical research is moving towards using immunocompentent models, which are required to assess immunomodulatory agents. Choosing the correct model from the variety available can be difficult, but is needed to help to efficiently progress novel agents. Download our White Paper to learn which human specific and mouse analogue models are available, and how to select the best model for any given immuno-oncology study.

閱讀更多

Target identification and MOA studies are a vital early stage in cancer drug development, and require disease-relevant cell-based platforms, with linked later stage models to accelerate lead compounds. Discover how CrownBio’s integrated oncology portfolio of in vitro, in vivo, and ex vivo products and services help advance target identification and MOA studies within drug discovery programs, allowing go/no-go decisions to be made with confidence.

閱讀更多

Human tumor bearing humanized mouse models are needed for the preclinical assessment of human-specific immunotherapeutics. Given the complexity of these models (including hCD34+ and hPBMC mice combined with PDX and traditional xenografts), the key to optimizing their use is to bring together an in depth knowledge of each model features and limitations, with bespoke study designs, centred around the specific question being asked in each study. Download our White Paper to discover different immune system humanization strategies and how these result in models with differing pros and cons, alongside successful model utilization in cancer pharmacology case studies.

閱讀更多

腫瘤藥物研究目前為改進新藥研發效率和性價比,急需解決過高的新藥晚期臨床實驗失敗率問題。利用人源腫瘤異體移植模型(PDX)這一目前最具預測性的臨床前實驗模型進行精準分析,能夠鑒定可以用于以對治療的敏感度進行患者成層的分子生物標記物或基因簽名,從而降低藥物研發失敗率。讓中美冠科生物的精準分析白皮書幫助您在臨床前了解哪些患者更能從您的治療中獲益。

閱讀更多

New approaches are needed in oncology, to better predict clinical efficacy within preclinical assessment. Mouse Clinical Trials (MCT) using patient-derived xenograft (PDX) models are a highly predictive alternative to traditional drug discovery methods, providing a more clinically relevant situation, a better perspective of patient-to-patient heterogeneity, and a framework for biomarker discovery. Download our White Paper to discover the various types of MCT, and identify which method will best progress any given drug development program.

閱讀更多

關注微信公眾號

彩票开奖云南快乐10分 可下分的手机捕鱼游戏 网赚平台app 优乐精江西麻将最新版 四人麻将免费 二分彩是不是骗局 网络捕鱼游戏赚分技巧 股票k线图下载 黑龙江彩6十1开奖结果 九乐棋牌经典版 20选5开奖直播